BG-89894 / CSPC Pharma, BeOne Medicines - LARVOL DELTA

An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=29 | Terminated | Sponsor: BeOne Medicines | Recruiting ➔ Terminated; The study was discontinued following an internal decision by the sponsor

Trial termination • Oncology • Solid Tumor • MTAP

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=235 | Sponsor: BeOne Medicines | N=97 ➔ 235

Enrollment change • First-in-human • Oncology • Solid Tumor • MTAP

BeOne shelves 5 cancer programs… (FierceBiotech) - "Four of the five cancer assets have been discontinued entirely, BeOne announced in its May 6 earnings presentation (PDF). These are the EGFR-targeting BG-60366, which was in development for lung cancer; a pan-KRAS inhibitor called BGB-53038 for lung and gastrointestinal tumors; MAT2A inhibitor BG-89894 for lung and solid tumors; and CDK2 inhibitor BG-68501, for breast and solid tumors....A study of the CCR8 antibody BGB-A3055 in solid tumors has also been terminated, but this asset has not been fully discontinued, a BeOne spokesperson confirmed to Fierce Biotech."

Discontinued • Trial termination • Esophageal Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Triple Negative Breast Cancer

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=525 | Recruiting | Sponsor: BeOne Medicines | N=244 ➔ 525 | Trial completion date: Jan 2029 ➔ Sep 2027 | Trial primary completion date: Jan 2029 ➔ Sep 2027

Enrollment change • First-in-human • Trial completion date • Trial primary completion date • Oncology • Solid Tumor • MTAP

An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=29 | Terminated | Sponsor: BeOne Medicines | Active, not recruiting ➔ Terminated; The study was discontinued following an internal decision by the sponsor

Trial termination • Oncology • Solid Tumor • MTAP

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=244 | Recruiting | Sponsor: BeOne Medicines | N=79 ➔ 244

Enrollment change • First-in-human • Oncology • Solid Tumor • MTAP

A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of PRMT5 Inhibitor BGB-58067 Alone and in Combination with Anticancer Agents in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=63 | Recruiting | Sponsor: BeOne Medicines | N=44 ➔ 63

Enrollment change • First-in-human • Oncology • Solid Tumor • MTAP

An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=29 | Active, not recruiting | Sponsor: BeOne Medicines | Recruiting ➔ Active, not recruiting | N=140 ➔ 29 | Trial completion date: Dec 2028 ➔ Apr 2026

Enrollment change • Enrollment closed • Trial completion date • Oncology • Solid Tumor • MTAP

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=244 | Recruiting | Sponsor: BeOne Medicines | Trial completion date: Jun 2027 ➔ Jan 2029 | Trial primary completion date: Jun 2027 ➔ Jan 2029

Trial completion date • Trial primary completion date • Oncology • Solid Tumor

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=237 | Recruiting | Sponsor: BeiGene | N=92 ➔ 237 | Trial completion date: Nov 2026 ➔ Jun 2027 | Trial primary completion date: Nov 2026 ➔ Jun 2027

Enrollment change • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=140 | Recruiting | Sponsor: BeiGene | Trial completion date: Dec 2026 ➔ Dec 2028

Trial completion date • Oncology • Solid Tumor

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of SYH2039 Tablets in Adults with Advanced Solid Tumors (ChiCTR) - P1 | N=186 | Recruiting | Sponsor: Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences); Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sci

New P1 trial • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MTAP

Study of SYH2039 in Participants with Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=186 | Recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor (Businesswire) - "BeiGene...announced it has entered into a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology...for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors....'This MAT2A inhibitor is a valuable addition to our solid tumor pipeline, and we’re eager to explore its potential, particularly in combination with our internally developed PRMT5 inhibitor, BGB-58067'....BGB-58067, which is on track to enter the clinic before the end of the year, is designed to avoid on-target hematological toxicity seen with first-generation PRMT5 inhibitors....Under the terms of the agreement, BeiGene has an exclusive license to develop, manufacture and commercialize SYH2039 worldwide. CSPC will receive upfront and time-based payments totaling $150 million and will be eligible for payments upon the achievement of certain development and commercial milestones and tiered royalties."

Licensing / partnership • New trial • Solid Tumor

Study of SYH2039 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=186 | Not yet recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor